Myovant Sciences, Ltd. (NYSE: MYOV) aspires to be the leading healthcare company focused on innovative treatments for women’s health and prostate cancer designed to improve the lives of millions. We are on a mission to develop and deliver empowering medicines for women’s health and prostate cancer through purpose-driven science and transformative advocacy. Being part of Myovant Sciences is being part of something special. The focus of the organization could not be clearer – we were built with the DNA to hold a personal passion to give our customers and our patients MORE. We are looking for passionate and hard-working individuals who share our excitement for this mission.
Myovant Sciences’ lead product candidate is relugolix, an oral, once-a day small molecule that acts as a GnRH receptor antagonist. The company has three clinical programs for relugolix consisting of five international Phase 3 clinical trials, two in women with heavy menstrual bleeding associated with uterine fibroids (LIBERTY 1 & 2), two in women with endometriosis-associated pain (SPIRIT 1 & 2), and one in men with advanced prostate cancer (HERO). Positive results have been announced in all five trials. Two New Drug Applications have been submitted to the FDA, including one for relugolix for men with advanced prostate cancer in April 2020 and one for relugolix combination tablet for women with heavy menstrual bleeding and uterine fibroids in May 2020. In August, Myovant announced that its NDA for once-daily, oral relugolix combination tablet for the treatment of women with heavy menstrual bleeding associated with uterine fibroids had been accepted for review by the FDA. The FDA has set a target action date of June 1, 2021 under the Prescription Drug User Fee Act (PDUFA). A third NDA is expected to be filled for relugolix combination tablet for women with pain associated with endometriosis.
In anticipation of FDA approval, Myovant is preparing for inaugural commercial launches in the U.S. of two distinctly branded products, relugolix combination tablet for women with heavy menstrual bleeding associated with uterine fibroids and pain associated with endometriosis and relugolix monotherapy tablet for men with advanced prostate cancer.
We are currently seeking a qualified, highly motivated, experienced individual for the position of Regional Sales Director, Gulf Coast. This role will build a versatile field team from the ground up and drive multiple successful product launches in Women’s Health. The position reports to the Senior Area Sales Director, West. The location of the position is field based.
The Regional Sales Director (RSD), Gulf Coast will build, lead, and manage a team of sales representatives across a defined geography. The RSD will develop a best-in-class launch selling team and will maximize revenue growth and profitability. This individual will be a highly collaborative leader who is energetic and driven and thrives in a nimble, start-up organization. The RSD will demonstrate a sense of urgency to prepare and successfully execute a new product launch plan for the assigned geography in addition to driving results through the sales team that is consistent with Myovant’s goals, mission, and values.
Essential Duties and Responsibilities
Core Competencies, Knowledge, and Skill Requirements
TRAVEL, PHYSICAL DEMANDS, AND WORK ENVIRONMENT
Disclaimer: The above statements are intended to describe the general nature and level of work being performed by people assigned to this classification. They are not to be construed as an exhaustive list of all responsibilities, duties, and skills required of personnel so classified. All personnel may be required to perform duties outside of their normal responsibilities from time to time, as needed.
If you require any accommodations, please email .
Equal Employment Opportunity
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.